{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Al Hadidi S"],"pubmed_abstract":["<h4>Abstract</h4>The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan-based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)-defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP-defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 3"],"journal":["Blood advances"],"pagination":["703-707"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10845028"],"repository":["biostudies-literature"],"pubmed_title":["Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up."],"pmcid":["PMC10845028"],"pubmed_authors":["Sawyer J","Bailey C","Barlogie B","Ababneh OE","Al Hadidi S","Panozzo S","Thanendrarajan S","Shaughnessy JD","Cottler-Fox M","Smith R","Zangari M","Tricot G","Alapat D","Zhan F","Schinke CD","van Rhee F"],"additional_accession":[]},"is_claimable":false,"name":"Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.","description":"<h4>Abstract</h4>The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan-based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)-defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP-defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 3","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-07-15T09:20:43.365Z","creation":"2024-11-08T09:54:13.529Z"},"accession":"S-EPMC10845028","cross_references":{"pubmed":["38052037"],"doi":["10.1182/bloodadvances.2023011601"]}}